The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee

Annals of the Rheumatic Diseases

Volumn 66, Issue 2, 2007, Pages 215-221

  Coupé, Veerle M H ^a   Veenhof, Cindy ^b   Van Tulder, Maurits W ^a   Dekker, Joost ^a   Bijlsma, Johannes W J ^c   Van Den Ende, Cornelia H M ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FUNCTIONAL ASSESSMENT; HEALTH CARE; HIP OSTEOARTHRITIS; HUMAN; KINESIOTHERAPY; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICAL ACTIVITY; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; EXERCISE THERAPY; FAMILY PRACTICE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; NETHERLANDS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 33846882425     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.054478     Document Type: Article

References (30)

1. Miedema H. Reuma-onderzoek meerdere echelons (Rome): basisrapport. (Rheumatism-research on different levels of the health care system: basis report), NIPG-publication 93.099. Leiden: NIPG-TNO, 1994.
2. Fransen M, McConnell S, Bell M. Exercise for osteoarthritis of the hip or knee. Cochrane Database Syst Rev 2003;3:CD004286 [Review].
3. Van Baar M. Effectiveness of exercise therapy in osteoarthritis of hip or knee. Dissertation. 1998.
4. Veenhof C, Köke AJA, Dekker J, Oostendorp RA, Bijlsma JWJ, van Tulder MW, et al. Effectiveness of behavioral graded activity in patients with osteoarthritis of hip and/or knee: a randomized clinical trial. Arthritis Rheum 2006;5:925-34.
5. Veenhof C, Dekker J, Bijlsma JW, van den Ende CH. Influence of various recruitment strategies on the study population and outcome of a randomized controlled trial involving patients with osteoarthritis of the hip or knee. Arthritis Rheum 2005;53:375-382.
6. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-1049.
7. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-514.
8. Fordyce WE, Fowler RS Jr. Lehmann JF, Delateur BJ, Sand PL, Trieschmann RB. Operant conditioning in the treatment of chronic pain. Arch Phys Med Rehabil 1973;54:399-408.
9. Lindstrom I, Ohlund C, Eek C, Wallin L, Peterson LE, Fordyce WE, et al. The effect of graded activity on patients with subacute low back pain: a randomized prospective clinical study with an operant-conditioning behavioral approach. Phys Ther 1992;72:279-290.
10. Vogels EMHM, Hendriks HJM, Van Baar ME, Dekker J, Hopman-Rock M, Oostendorp RA. Clinical practice guidelines for physical therapy in patients with osteoarthritis of the hip or knee. Amersfoort: KNGF 2001.
11. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833- 1840.
12. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997;24:799-802.
13. Heijden GJMGvd. Shoulder disorder treatment: Efficacy of ultrasoundtherapy and electrotherapy. 1996.
14. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
15. Oostenbrink JB, Koopmanschap MA, Van Rutten FFH. Handleiding voor kostenonderzoek. Methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. (Handbook for cost studies, methods and guidelines for economic evaluations in health care). The Hague: Health Care Insurance Council, 2000.
16. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002;20:443-454.
17. Royal Dutch Society for pharmacy. Z-index. G-standaard. The Hague, The Netherlands: Z-index, 2002.
18. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996;10:460-466.
19. Busschbach JJ, Brouwer WB, van der DA, Passchier J, Rutten FF. An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer's disease. Pharmacoeconomics 1998;13:21-34.
20. Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005;14:763-76.
21. Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 2005;14:471-485.
22. UK Beam Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care. BMJ 2004;329:1377-80.
23. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219-3236.
24. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-340.
25. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-1200.
26. Pham T, van der HD, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389-399.
27. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.
28. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300: 230-235.
29. Richardson G, Manca A. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ 2004;13:1203-1210.
30. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998;7:723-740.